Lilly To Develop Cancer Vaccine Products with CureVac -- Market Talk
October 18 2017 - 9:23AM
Dow Jones News
8:53 ET - Eli Lilly has reached an agreement with German
drugmaker CureVac to develop up to five potential cancer-vaccine
products. The companies plan to use messenger RNA technology to
trigger the human immune system to attack cancer. Investors and
researchers have been interested in the potential of messenger RNA
as a tool to develop targeted therapies to treat a wide range of
diseases and ailments. CureVac, which earns $50M upfront and gets
EUR45 million equity from Lilly, can earn more than $1.7B on
commercialization milestones in addition to royalties. Shares in
the Indianapolis pharmaceutical company rise 1% premarket to
$86.95. (bowdeya.tweh@wsj.com; @BowKnowsBiz)
(END) Dow Jones Newswires
October 18, 2017 09:08 ET (13:08 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
